|Debt, 7/2012 ||$4.09M|
|Debt, 2/2013 ||$650k|
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna™, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.
Opexa Therapeutics, Inc. was established in 2004 through the merger of two independent companies PharmaFrontiers and Opexa Pharmaceuticals. PharmaFrontiers had licensed novel stem cell technology from the University of Chicago and Opexa Pharmaceuticals had licensed novel T-cell technology from Baylor College of Medicine. The bringing together of these two novel and independent platforms propelled Opexa Therapeutics, Inc. to the forefront of cell therapy where it remains a leading force today.
Opexa is located in The Woodlands, Texas north of Houston on one acre of forested land and houses its cGMP facility, research laboratories and corporate offices.